Aravive surges on positive data from kidney cancer study
24/06/2021 12:37
** Shares of biotechnology firm Aravive Inc ARAV.O jump
28% premarket to $6.92, their highest in nearly three months
** Stock set for best day since Nov 2019
** ARAV announces positive initial results from phase-1b
study of its AVB-500 treatment for kidney cancer; treatment was
well tolerated with no unexpected findings urn:newsml:reuters.com:*:nGNX8VKl2B
** Co plans to expand dosing to more patients to determine
initiating phase-2 study
** ARAV down ~5.7% YTD
(Reporting by Ambar Warrick)
((Ambar.Warrick@thomsonreuters.com; +91-80-6182-2837;))